Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AMAVIT D3 is a line of dietary supplements developed and manufactured by the Polish pharmaceutical company Amara. The product line contains vitamin D3 (cholecalciferol) and is designed to support the maintenance of healthy bones and teeth, proper muscle function, and the normal operation of the immune system. AMAVIT D3 is available in various formulations and strengths tailored to different age groups, including AMAVIT D3 Baby (400 IU drops in MCT oil), AMAVIT D3 Junior (1000 IU orally disintegrating tablets), AMAVIT D3 (2000 IU orally disintegrating tablets or soft capsules), and AMAVIT D3 MAX (4000 IU orally disintegrating tablets). The orally disintegrating tablet (ODT) formulations feature a pleasant lemon flavor and are designed to dissolve quickly in the mouth without the need for water, making them suitable for individuals who have difficulty swallowing capsules or tablets.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on AMAVIT D3.